Risk Communication

Risk communication is the process of conveying probabilistic information about genetic conditions in a way that patients can understand, retain, and use to make informed decisions. Effective risk communication accounts for numeracy levels, cognitive biases, and the emotional context in which information is received.

• Numeric formats: Risk can be expressed as fractions (1 in 4), percentages (25%), or frequencies (25 out of 100). Natural frequencies (e.g., "Out of 100 people like you, 25 would be affected") are generally easier for patients to understand than percentages or fractions. Use consistent denominators when comparing risks.
• Verbal descriptors: Terms like "high risk," "low risk," or "unlikely" are imprecise and mean different things to different people. When verbal descriptors are used, they should be accompanied by numeric values. A patient may hear "low risk" and interpret it as zero, or hear "increased risk" and interpret it as near-certainty.
• Visual aids: Pictographs (icon arrays), pie charts, bar graphs, and risk ladders can enhance understanding, especially for patients with low numeracy. Pictographs (showing 100 stick figures with affected individuals highlighted) are among the most effective visual tools studied.
• Framing effects: The same risk can be perceived differently depending on how it is framed. "There is a 75% chance the baby will be unaffected" (positive frame) feels different from "There is a 25% chance the baby will be affected" (negative frame), even though they are mathematically identical. Best practice is to present both frames to minimize bias.
• Absolute vs. relative risk: Absolute risk is the probability of an event occurring (e.g., 2% lifetime risk of ovarian cancer). Relative risk compares one group to another (e.g., "3 times the average risk"). Relative risk can be misleading: a 3-fold increase from 1% to 3% sounds alarming but represents a small absolute change. Always provide the absolute risk alongside any relative risk.
• Communicating uncertainty (VUS): Variants of uncertain significance require careful communication. Explain that current evidence is insufficient to classify the variant as disease-causing or benign. Emphasize that medical management should be based on personal and family history, not the VUS. Discuss the possibility of reclassification over time and the plan for follow-up.
• Shared decision-making frameworks: Use a structured approach: (1) present the decision to be made, (2) describe the options, (3) discuss benefits, risks, and limitations of each option, (4) explore the patient's values and preferences, and (5) arrive at a decision together. Tools like decision aids (pamphlets, videos, interactive websites) can supplement counselor-led discussions.
• Anchoring bias: Patients (and providers) tend to anchor on the first piece of information they receive. If a patient was previously told their risk is "very low," they may have difficulty adjusting when new information (e.g., a family history update) raises the risk. Be aware of anchoring and address it explicitly.
• Risk perception and affect: Patients interpret risk through an emotional lens. A 5% risk of a devastating condition may feel subjectively higher than a 20% risk of a treatable condition. The emotional weight of the outcome, not just the probability, drives decision-making.

• A couple is told their child has a 1 in 4 (25%) chance of being affected with an autosomal recessive condition. The mother says, "So the next three children will be fine." Correct this misunderstanding: each pregnancy is an independent event with the same 25% risk. The "gambler's fallacy" is common and must be addressed clearly.
• A patient with a BRCA2 pathogenic variant asks about her ovarian cancer risk. You should present the absolute lifetime risk (approximately 10-17%) rather than only the relative risk ("several times higher than average"). Combine with a visual aid if possible.
• A patient receives a VUS result on a hereditary cancer panel. She asks, "Does this mean I have cancer risk?" Explain that a VUS does not change medical management at this time, that her care should be guided by her personal and family history, and that the laboratory will re-evaluate the variant as more data become available. Offer to recontact her if the classification changes.
• A prenatal patient is told her cell-free DNA screen is "positive" for Trisomy 21 with a PPV of 80%. She believes the baby definitely has Down syndrome. Clarify the difference between a screening result and a diagnostic result: an 80% PPV means that in 20% of positive screens, the baby is unaffected. Offer diagnostic testing (amniocentesis or CVS) for confirmation.